JP2004513081A - ＮＮＴ−１インヒビターを使用してＩｇＥ関連疾患を治療するための方法および組成物 - Google Patents

ＮＮＴ−１インヒビターを使用してＩｇＥ関連疾患を治療するための方法および組成物 Download PDF

Info

Publication number
JP2004513081A
JP2004513081A JP2002520896A JP2002520896A JP2004513081A JP 2004513081 A JP2004513081 A JP 2004513081A JP 2002520896 A JP2002520896 A JP 2002520896A JP 2002520896 A JP2002520896 A JP 2002520896A JP 2004513081 A JP2004513081 A JP 2004513081A
Authority
JP
Japan
Prior art keywords
nnt
ige
polypeptide
binding agent
selective binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002520896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004513081A5 (enExample
Inventor
セナルデイ，ジヨルジヨ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2004513081A publication Critical patent/JP2004513081A/ja
Publication of JP2004513081A5 publication Critical patent/JP2004513081A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002520896A 2000-08-18 2001-08-17 ＮＮＴ−１インヒビターを使用してＩｇＥ関連疾患を治療するための方法および組成物 Pending JP2004513081A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22643600P 2000-08-18 2000-08-18
US09/931,704 US6849260B2 (en) 2000-08-18 2001-08-16 Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
PCT/US2001/025906 WO2002015977A2 (en) 2000-08-18 2001-08-17 Methods and compositions for treating ige-related disease using nnt-1 inhibitors

Publications (2)

Publication Number Publication Date
JP2004513081A true JP2004513081A (ja) 2004-04-30
JP2004513081A5 JP2004513081A5 (enExample) 2006-01-05

Family

ID=26920541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002520896A Pending JP2004513081A (ja) 2000-08-18 2001-08-17 ＮＮＴ−１インヒビターを使用してＩｇＥ関連疾患を治療するための方法および組成物

Country Status (7)

Country Link
US (1) US6849260B2 (enExample)
EP (1) EP1309374A2 (enExample)
JP (1) JP2004513081A (enExample)
AU (2) AU2001283451A1 (enExample)
CA (1) CA2419274A1 (enExample)
MX (1) MXPA03001434A (enExample)
WO (1) WO2002015977A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076288A2 (en) * 2005-01-11 2006-07-20 Five Prime Therapeutics, Inc. Dna constructs for long-term expression of intravascularly injected naked dna

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100365064B1 (ko) 1994-10-17 2003-04-11 훽스트파마슈티칼스앤드케미칼스가부시키가이샤 I형알레르기성질환의예방및치료제
EP0839155B1 (en) 1995-07-17 2004-10-13 Medivir UK Ltd CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
IL154543A0 (en) 1997-02-03 2003-09-17 Amgen Inc The neurotrophic factor nnt-1
CA2295326A1 (en) 1997-06-30 1999-01-07 Human Genome Sciences, Inc. Cardiotrophin-like cytokine
GB9913327D0 (en) 1999-06-08 1999-08-11 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
AU2001283451A1 (en) 2002-03-04
EP1309374A2 (en) 2003-05-14
WO2002015977A2 (en) 2002-02-28
CA2419274A1 (en) 2002-02-28
WO2002015977A3 (en) 2002-11-28
MXPA03001434A (es) 2004-12-13
AU2005232321A1 (en) 2005-12-01
US20020041873A1 (en) 2002-04-11
US6849260B2 (en) 2005-02-01

Similar Documents

Publication Publication Date Title
ES2257739T3 (es) Antigenos ctla-8 de primate purificados y reactivos relacionados.
US20090280082A1 (en) Methods for treating autoimmune disorders
US20100080809A1 (en) Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
US20120141411A1 (en) Uses of IL-174 Antagonists for Inhibiting A Th2 Immune Response
JP4864278B2 (ja) 脱髄疾患を処置する方法
AU2001288286A1 (en) Methods for treating demyelinating diseases
US6849260B2 (en) Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
JP2000511418A (ja) ヒトインターロイキン―１ｊおよびそのアンタゴニスト
JP2002514067A (ja) 神経栄養因子ｎｎｔ−１
US20040096446A1 (en) Methods for treating demyelinating diseases
CN114901313A (zh) 急性期的视神经脊髓炎的预防或治疗剂
US20050142108A1 (en) Methods of modulating cytokine activity; related reagents
CN114945385A (zh) 痴呆症的预防或治疗剂
Doll Development of therapeutic proteins for the treatment of rheumatoid arthritis and chronic cardiac rejection
AU2007201935A1 (en) Methods for treating demyelinating disease

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081028